Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Shigella Vaccines Pipeline

24 Aug 2022

Abstract excerpt

Shigella is the leading cause of global diarrheal deaths that currently lacks a licensed vaccine. Shigellosis drives antimicrobial resistance and leads to economic impact through linear growth faltering. Today, there is a robust pipeline of vaccines in clinical development which are broadly divided into parenteral glycoconjugate vaccines, consisting of O-antigen conjugated to carrier proteins, and oral live...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Escherichia coli research studies
Share to Hepatitis Viruses Studies and Epidemiology
Share to Viral gastroenteritis research and epidemiology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36146457
DOI: 10.3390/vaccines10091376

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Shigella Vaccines PipelinePMID 36146457Read ↗

Status of vaccine research and development for ShigellaSemantic proximity Read ↗

Frontiers in Shigella Vaccine DevelopmentSemantic proximity Read ↗

The identification of novel immunogenic antigens as potential Shigella vaccine componentsSemantic proximity Read ↗

Towards a Four-Component GMMA-Based Vaccine against ShigellaSemantic proximity Read ↗

A next-generation GMMA-based vaccine candidate to fight shigellosisSemantic proximity Read ↗

Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I StudySemantic proximity Read ↗

Towards establishing correlates of protection against shigellosis: assessing immunological endpoints across immune responses to the Shigella sonnei Generalized Modules for Membrane Antigens (GMMA) candidate vaccine (1790GAHB).Semantic proximity Read ↗

Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protectionSemantic proximity Read ↗

Vaccines Against Shigella and Enterotoxigenic Escherichia coli: A summary of the 2018 VASE ConferenceSemantic proximity Read ↗

Towards establishing a correlate of protection against shigellosis: assessing immunological endpoints across immune responses to the Shigella sonnei 1790GAHB GMMA investigational vaccineSemantic proximity Read ↗

Protein-specific immune response elicited by the Shigella sonnei 1790GAHB GMMA-based candidate vaccine in adults with varying exposure to ShigellaSemantic proximity Read ↗

From Concept to Clinical Product: A Brief History of the Novel Shigella Invaplex Vaccine’s Refinement and EvolutionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.